A Study of PLX51107 in Advanced Malignancies

ClinicalTrials.gov ID: NCT02683395

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02683395. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies

Study identification

NCT ID: NCT02683395
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Plexxikon; Industry
Enrollment: 50 participants

Conditions and interventions

Conditions

Interventions

PLX51107 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2016 (Type not available)
Primary completion: Sep 2018 (Actual)
Completion: Sep 2018 (Actual)
Last update posted: Dec 24, 2018

2016 – 2018

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Columbia University Medical Center	New York	New York	10032	—
The Ohio State University Stephanie Spielman Comprehensive Breast Center	Columbus	Ohio	43212	—
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	—
MUSC/ Hollings Cancer Center	Charleston	South Carolina	29425	—
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02683395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 24, 2018 · Synced Nov 14, 2026